JP-CSPC@EC2603A(16865.HK)

Last Updated 08:00:00
longbridge loading
Company Encyclopedia
View More
name
JP-CSPC@EC2603A
16865.HK
News
View More

New Drug Administration Implementation Regulations Released: Allowing Innovative Drugs to be Produced in Segments, Accelerating the Market Launch of Good Medicines

The State Council has announced the newly revised "Regulations for the Implementation of the Drug Administration Law," which will take effect on May 15, 2026. This is the first comprehensive revision of the regulations in over twenty years. The key points of the revision include: improving the drug registration system, establishing exclusive market periods for pediatric drugs and drugs for rare diseases for the first time (up to 2 years and 7 years respectively), clarifying four new drug expedited approval pathways; strengthening the responsibilities of online drug trading platforms and regulating online drug sales; allowing segmented commissioning of innovative drug production to optimize the industrial supply chain; and shifting the regulatory focus from enterprises to drug marketing authorization holders, enhancing lifecycle supervision

Wallstreetcn·
HK
01093
+6.14%
HK
01177
+2.40%
Wallstreetcn·
HK
01093
+6.14%
HK
01177
+2.40%

CSPC PHARMA granted over 46.46 million shares as rewards

CSPC PHARMA granted 46.4625 million restricted shares to 727 employees under the share award plan, accounting for approximately 0.4% of the total issued shares. Based on the closing price of 9.81 yuan, the amount involved is approximately 456 million yuan. The awarded shares will vest in three batches, with the number granted depending on the respective performance targets, with a deadline of December 31, 2028

AASTOCKS·
HK
01093
+6.14%
AASTOCKS·
HK
01093
+6.14%

CSPC Pharmaceutical Grants 46.5 Million Restricted Shares to 727 Employees

CSPC Pharmaceutical Group has granted 46.5 million restricted shares to 727 employees as part of its equity incentive scheme. This represents about 0.4% of its issued share capital, with shares vesting in three tranches from January 2027 to January 2029, contingent on performance targets. The company retains 61.6 million shares for future grants. The latest analyst rating for CSPC stock (HK:1093) is a Hold with a price target of HK$10.50. CSPC focuses on the research, development, and sale of pharmaceuticals in both domestic and international markets.

Tip Ranks·
HK
01093
+6.14%
Tip Ranks·
HK
01093
+6.14%

CSPC PHARMA's subsidiary, CSPC Innovation, reported a loss of at least 170 million RMB last year

CSPC PHARMA's subsidiary, CSPC Innovation, issued a profit warning, expecting a loss of between 170 million and 250 million RMB for the fiscal year 2025, compared to a profit of 53.73 million RMB in the previous year. The reasons for the loss include an increase in R&D expenses to approximately 1 billion RMB, the acquisition of a minority stake in the controlling subsidiary, Jushi Biotech, leading to a greater impact on net profit, and a decrease in the gross profit margin of the functional raw materials business

AASTOCKS·
HK
01093
+6.14%
AASTOCKS·
HK
01093
+6.14%

The Hang Seng Index rose 268 points in half a day, with the 27,000 mark "gained and lost," as innovative drug stocks collectively surged. Three new stocks had a weak finish｜Hong Kong Stock Market Afternoon Session

The Hang Seng Index opened 350 points higher this morning, reaching a maximum of 27,143 points during the day, and closed at 26,877 points, up 268 points or 1.01%. Alibaba rose 3.5%, JD.com rose 1.11%, and Tencent rose 0.48%; Xiaomi, Meituan, and Baidu, on the other hand, declined. Innovative drug stocks collectively rose, with WuXi AppTec up 7.67% and CSPC PHARMA up 5.5%. Automotive stocks generally rose due to the consensus reached on electric vehicles between China and Europe, with BYD up 3.19%. The newly listed stocks today showed volatility, with Zhaoyi Innovation once rising over 53.5%

Stheadline·
HK
01093
+6.14%
Stheadline·
HK
01093
+6.14%
Posts
View More
© 2026 Longbridge｜Disclaimer